What’s the current market cap for Takeda Pharmaceutical stock?

Takeda Pharmaceutical (TAK) has a market cap of $48bn as of June 21, 2026.

What is the P/E ratio for Takeda Pharmaceutical stock?

The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 21.11 as of June 21, 2026.

Does Takeda Pharmaceutical stock pay dividends?

Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of June 21, 2026, the dividend rate is $0.52765 and the yield is 3.22%. Takeda Pharmaceutical has a payout ratio of 162.65% on a trailing twelve-month basis.

When is the next Takeda Pharmaceutical dividend payment date?

The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.

What is the beta indicator for Takeda Pharmaceutical?

Takeda Pharmaceutical (TAK) has a beta rating of 0.09. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Takeda Pharmaceutical stock | $TAK Share Price

About Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.

Ticker

$TAK

Sector

Health

Primary listing

NYSE

Employees

47,455

Headquarters

Chuo, Japan

Website

www.takeda.com

TAK Metrics

BasicAdvanced

$48bn

21.11

$0.74

0.09

$0.53

3.22%

What the Analysts think about TAK

Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.

Bulls say / Bears say

Positive Phase III readout for its AI-developed psoriasis asset zasocitinib demonstrated safety and efficacy, supporting near-term regulatory filings and potential launch in 2026 (Bloomberg).

Takeda’s restructuring, including cuts of about 4,500 jobs in FY2026, is projected to deliver JPY 100 billion in savings next year and over JPY 200 billion annually by FY2028, enhancing profitability and free cash flow for growth investments (Reuters).

The company delivered FY 2025 results in line with management guidance, leveraging operational expense savings to mitigate revenue headwinds while continuing to invest in future growth (Nasdaq).

Persistent generic erosion of its ADHD franchise VYVANSE continues to depress revenue, with revenues down 3.3% year-over-year in the first nine months and the headwind expected to linger into FY2025 (FiercePharma).

The $62 billion acquisition of Shire in 2019 added significant debt and complexity, burdening the balance sheet and constraining integration efforts and financial flexibility, as highlighted in its ongoing restructuring (Reuters).

A U.S. jury found Takeda liable in antitrust litigation over its constipation drug Amitiza, imposing an $885 million damages verdict with potential treble damages up to $2.47 billion and triggering a JPY 402.5 billion provision for legal proceedings, underscoring significant litigation risk (Reuters, Reuters)

Data summarised monthly by Lightyear AI. Last updated on 18 Jun 2026.

TAK Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

TAK News

AllArticlesVideos

New Pivotal Study Data Show Takeda's Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

Business Wire·5 days ago

Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial

Reuters·1 week ago

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

Business Wire·2 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.